单细胞追踪揭示黑色素瘤 TIL 治疗过程中肿瘤反应性 T 细胞的可塑性
Single-cell tracking reveals tumor-reactive T cell plasticity during melanoma TIL therapy.
TIL(肿瘤浸润淋巴细胞)过继细胞治疗可在转移性黑色素瘤中诱导持久缓解,然而在体外扩增过程中及回输后,调控肿瘤反应性T细胞命运的克隆和转录动态仍知之甚少。
英文原题:Lnk Governs chemokine-directed trafficking of CD8(+) T cells in melanoma.
Lnk是一种衔接蛋白,在造血和免疫细胞中减弱细胞因子受体信号传导,但其在实体瘤内CD8+ T细胞行为中的作用尚不明确。
Lnk是一种衔接蛋白,可减弱造血和免疫细胞中的细胞因子受体信号传导,但其在实体瘤内CD8+ T细胞行为中的作用尚未明确。我们利用小鼠黑色素瘤模型,比较了Lnk缺陷小鼠与野生型对照组的肿瘤生长和免疫浸润情况,并评估了CD8+ T细胞向黑色素瘤细胞产生的趋化因子信号的迁移。Lnk缺陷小鼠形成的肿瘤较小,且瘤内CD8+细胞毒性T细胞数量更多。两组间的肿瘤趋化因子谱相当,包括CXCL2等白细胞介素-8家族信号的高水平表达,但缺乏Lnk的CD8+ T细胞在离体条件下向黑色素瘤来源信号的迁移增强,并在体内更有效地在肿瘤内积聚。药理学抑制CXCR1/2消除了这种迁移优势。在白细胞介素-8家族趋化因子刺激下,Lnk缺陷的CD8+ T细胞表现出STAT3和ERK信号通路激活增强。此外,反义介导的野生型T细胞中Lnk下调,在过继转移至野生型宿主后,导致其在黑色素瘤肿瘤内的积聚增强。这些发现表明Lnk是黑色素瘤中CD8+ T细胞CXCR1/2依赖性运输的负调控因子,并提示调节这一细胞内检查点可能改善T细胞向实体瘤的运输并增强过继性细胞免疫疗法的效果。
Lnk is an adaptor protein that attenuates cytokine receptor signaling in hematopoietic and immune cells, but its role in the behavior of CD8 + T cells within solid tumors is not well defined. Using a murine melanoma model, we compared tumor growth and immune infiltration in Lnk-deficient mice and in wild-type controls and evaluated CD8 + T cell trafficking toward chemokine signals produced by melanoma cells. Lnk-deficient mice developed smaller tumors containing greater numbers of intratumoral CD8 + cytotoxic T cells. Tumor chemokine profiles, including high levels of interleukin-8 family signals such as CXCL2, were comparable between groups, yet CD8 + T cells lacking Lnk showed enhanced migration toward melanoma-derived cues ex vivo and accumulated more effectively within tumors in vivo . Pharmacologic inhibition of CXCR1/2 abolished this migratory advantage. Upon stimulation with interleukin-8 family chemokines, Lnk-deficient CD8 + T cells exhibited increased activation of STAT3 and ERK signaling pathways. Moreover, antisense-mediated downregulation of Lnk in wild-type T cells resulted in enhanced accumulation within melanoma tumors following adoptive transfer into wild-type hosts. These findings identify Lnk as a negative regulator of CXCR1/2-dependent trafficking of CD8 + T cells in melanoma and suggest that modulating this intracellular checkpoint may improve T cell trafficking into solid tumors and enhance the effectiveness of adoptive cellular immunotherapies.
MEMBER ACCOUNT
登录成功会直接打开下一页。